

In the Senate of the United States,

June 22, 2023.

Resolved, That the bill from the House of Representatives (H.R. 1734) entitled “An Act to require coordinated National Institute of Standards and Technology science and research activities regarding illicit drugs containing xylazine, novel synthetic opioids, and other substances of concern, and for other purposes.”, do pass with the following

AMENDMENT:

Strike all after the enacting clause and insert the following:

1 ***SECTION 1. SHORT TITLE.***

2 *This Act may be cited as the “Testing, Rapid Analysis,*
3 *and Narcotic Quality Research Act of 2023” or the*
4 *“TRANQ Research Act of 2023”.*

5 ***SEC. 2. XYLAZINE DETECTION AND ANALYSIS.***

6 *(a) DEFINITIONS.—In this section:*

7 *(1) DIRECTOR.—The term “Director” means the*
8 *Director of the National Institute of Standards and*
9 *Technology.*

1 (2) *FEDERAL LABORATORY.*—*The term “Federal*
2 *laboratory” has the meaning given such term in sec-*
3 *tion 4 of the Stevenson-Wydler Technology Innovation*
4 *Act of 1980 (15 U.S.C. 3703).*

5 (3) *INSTITUTE.*—*The term “Institute” means the*
6 *National Institute of Standards and Technology.*

7 (4) *INSTITUTION OF HIGHER EDUCATION.*—*The*
8 *term “institution of higher education” has the mean-*
9 *ing given such term in section 101 of the Higher Edu-*
10 *cation Act of 1965 (19 U.S.C. 1001).*

11 (5) *NONPROFIT ORGANIZATION.*—*The term “non-*
12 *profit organization” means an organization described*
13 *in section 501(c)(3) of the Internal Revenue Code of*
14 *1986 and exempt from tax under section 501(a) of*
15 *such code.*

16 (6) *XYLAZINE.*—*The term “xylazine” means the*
17 *nonopioid tranquilizer methyl benzene compound fre-*
18 *quently used in veterinary medicine as an emetic and*
19 *sedative with analgesic and muscle relaxant prop-*
20 *erties.*

21 (b) *IN GENERAL.*—*The Director shall—*

22 (1) *support intramural basic measurement*
23 *science and research of the Institute to advance—*

24 (A) *analytical methods to identify, under-*
25 *stand, differentiate, and categorize substances*

1 *containing xylazine, novel synthetic opioids, or*
2 *other new psychoactive substances;*

3 *(B) measurement technologies to shorten*
4 *analysis timelines and enhance narcotic and*
5 *opioid detection and analysis capabilities;*

6 *(C) new data tools, techniques, and proc-*
7 *esses to identify and publicly disclose relevant*
8 *information concerning substances containing*
9 *xylazine, novel synthetic opioids, or other new*
10 *psychoactive substances; and*

11 *(D) such other areas as the Director deter-*
12 *mines to be critical to the development and de-*
13 *ployment of technologies to measure and analyze*
14 *the presence of xylazine, novel synthetic opioids,*
15 *and other new psychoactive substances;*

16 *(2) support activities to inform and expand the*
17 *development of near-real time spectrometry capabili-*
18 *ties regarding xylazine, novel synthetic opioids, and*
19 *other new psychoactive substances;*

20 *(3) convene and consult with organizations en-*
21 *gaged in the analysis of new psychoactive substances*
22 *to develop coordinated strategies and voluntary best*
23 *practices for the safe handling, transport, data-shar-*
24 *ing, and analysis of substances containing xylazine,*

1 *novel synthetic opioids, or other new psychoactive*
2 *substances, including—*

3 *(A) the Drug Enforcement Administration;*

4 *(B) the Centers for Disease Control and*
5 *Prevention;*

6 *(C) the National Institute on Drug Abuse;*

7 *(D) Federal laboratories;*

8 *(E) States and territories;*

9 *(F) State fusion centers;*

10 *(G) the private sector;*

11 *(H) intergovernmental organizations;*

12 *(I) institutions of higher education, and*

13 *(J) nonprofit organizations;*

14 *(4) establish or expand collaborative partner-*
15 *ships or consortia with other government agencies and*
16 *persons engaged in related research and development,*
17 *such as institutions of higher education, Federal lab-*
18 *oratories, public health agencies, intergovernmental*
19 *organizations, and the private sector, to enhance nar-*
20 *cotic and opioid detection and analysis capabilities*
21 *regarding xylazine, novel synthetic opioids, and other*
22 *new psychoactive substances; and*

23 *(5) encourage graduate and post-graduate re-*
24 *search to include detection and identification of*

1 (2) *MATTERS EVALUATED.*—*The study conducted*
2 *pursuant to paragraph (1) shall include an evalua-*
3 *tion of the following:*

4 (A) *The capabilities, including technologies*
5 *and analytical methods, of Federal, State, and*
6 *local agencies to detect and identify new*
7 *psychoactive substances such as xylazine.*

8 (B) *An analysis of timeframes for identi-*
9 *fication and development of technologies and*
10 *methods to identify new psychoactive substances*
11 *by Federal, State, and local agencies.*

12 (C) *Facilities, including laboratories, used*
13 *by Federal, State, and local agencies for the*
14 *identification of new psychoactive substances*
15 *such as xylazine.*

16 (D) *Federal grant programs to fund new*
17 *technology development to detect and identify*
18 *new psychoactive substances.*

19 (b) *REPORT.*—*Not later than 2 years after the date*
20 *of the enactment of this Act, the Comptroller General shall*
21 *submit to the Committee on Commerce, Science, and Trans-*
22 *portation of the Senate and the Committee on Science,*
23 *Space, and Technology of the House of Representatives a*
24 *report containing the findings of the Comptroller General*

- 1 *with respect to the study conducted pursuant to subsection*
- 2 *(a).*

Attest:

Secretary.

118TH CONGRESS
1ST SESSION

H.R. 1734

AMENDMENT